medigraphic.com

2008, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2008; 46 (3)

Cardiovascular Risk of Cyclooxygenase Selective Inhibitors

Terán-Estrada L, Miranda-Limón JM, Galván-Villegas F

Language: Spanish
References: 43
Page: 287-299
PDF size: 141.88 Kb.


ABSTRACT

It has been estimated that 30 million people worldwide take an nonsteroidal antiinflammatory drug (NSAID) daily. The main clinical objectives of these drugs are both to reduce joint pain and to improve joint function. However, gastrointestinal adverse events lead to the development of cyclooxygenase selective inhibitors (COXIB) with a better gastrointestinal safety profile. Since 1999, COXIB shown capacity to develop cardiovascular adverse events. Subsequent discoveries confirm overall risk of cardiovascular events. The increased cardiovascular risk occurred both in patients who were taking aspirin and in those who were not. Similar results with different COXIB appears to be a class effect of the COX-2 inhibitors, so patient risk factors must be identified and used in treatment decision making. Patients with gastrointestinal risk factors and no cardiovascular risk may benefit from use of a gastroprotective agent plus a nonselective nonsteroidal antiinflammatory drugs as a COXIB. We review assays whose objective was to study cardiovascular security of nonsteroidal antiinflammatory drugs and COXIB for known advantages and limitations of these drugs.


REFERENCES

  1. Xie W, Robertson DL, Simmons DL. Mitogen inducible prostraglandin G/H synthase: a new target for nonsteroidal antiinflammatory drugs. Drug Div Res 1992;25:249-265.

  2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with arthritis rheumatoid. N Engl J Med 2000;343:1520-1528.

  3. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247-1255.

  4. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-890.

  5. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-959.

  6. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-2288.

  7. Crofford LJ. Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use? Current Op Rheum 2002;14(3):225-230.

  8. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109(17):2068-2073.

  9. Bresalier SR, Sandler RS, Hui Quan, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.

  10. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;3521071-1080.

  11. Brophy JM, Lévesque LE and Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart 2007;93:189-194.

  12. Agrawal NG, Porras AG, Matthews CZ, Woolf EJ, Miller JL, Mukhopadhyay S, et al. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J Clin Pharmacol 2001;41:1106-1111.

  13. Schumacher HRJ, Boice J, Daikh D, Mukhopadhyay S, Malmstrom K, Ng J, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002;324: 1488-1492.

  14. Gottesdiener K, Schnitzer T, Fisher C, et al. Results of a randomized, dose ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology 2002;41:1052-1061.

  15. Matsumoto AK, Melian A, Mandel DR, Mcllwain HH, Borenstein D, Zhao PL, et al. A randomized controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29: 1623-1630.

  16. EDGE Study Group, INCONNU; Baraf HSV, FuentesalbaC, Greenwald M, Brzezicki J, O’Brien K, Soffer B, et al. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of etoricoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness (EDGE) trial. J Rheumatol 2007;34(2):408-420.

  17. Cannon CP, Curtis SP, FitzGerald GA. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Programme: a randomized comparison. Lancet 2006;368:1771-1781.

  18. Psaty BM, Weiss NS. NSAID trials and the choice of comparators-questions of public health importance. N Engl J Med 2007;356:328-330.

  19. Makarowski W, Zhao WW, Bevirt T, Recker DP. Efficacy and safety of the COX 2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double blind, placebo controlled comparison with naproxen. Osteoarthritis Cartilage 2002;10:290-296.

  20. Ormrod D, Wellington K, Wagstaf AJ. Valdecoxib. Drugs 2002;62(14):2059-2071.

  21. Ott E, Nussmeier NA, Duke PC. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2004;127(2):605.

  22. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-1091.

  23. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364(9434):665-674.

  24. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Artritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364 (9434):675-684.

  25. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci 1999;96:272-277.

  26. FitzGerald GA, Patrono C. The COXIBS, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-441.

  27. FitzGerald GA, Cheng Y, Austin S. COX-inhibitors and the cardiovascular system. Clin Exp Rheumatol 2001;19 (Suppl 25):S31-S36.

  28. Wallace JL, Mc Knight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-714.

  29. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease. Arthritis Rheum 2003;48:12-20

  30. Marcus AJ, Broekman MJ, Drosoupolos JH, et al. Inhibition of platelet recruitment by endothelial cell CD30/ecto-ADPase: significance for occlusive vascular diseases. Ital Heart J 2001;2:824-830.

  31. Cicmil M, Thomas JM, Leduc M, Bon C, Gibbins JM. Platelet endothelial cell adhesion molecule-1 signalling inhibits the activation of human platelets. Blood 2002;99:137-144.

  32. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001:286:954-959.

  33. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-890.

  34. Bulut D ,Liaghat S, Hanefeld C, Kol R Miebach, T, Mugge A. Selective cyclooxygenase-2 inhibition with parecoxib acutely impairs endotheliumdependent vasodilatation in patients with essential hypertension. J Hypertens 2003;21(9):1663-1667.

  35. Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A. A multinational randomised, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Family Practice 2002;3:10.

  36. Van Hecken A, Schwartz JI, Depre M, De Lepeleire I, Dallob A, Tanaka W, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40: 1109-1120.

  37. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002;162(10):1111-1115.

  38. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162:1105-1110.

  39. Solomon DH, Glynn RJ, Levin R. Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch Intern Med 2002;162:1099-1104.

  40. Ray WA, Stein CM, Hall K. Non-steroidal antiinflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118-123.

  41. Mamdani M, Rochon P, Juurlink D, Anderson GM, Kopp A, Naglie G, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on shortterm risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163(4):481-486.

  42. Kurth T, Glynn RJ, Walter AM, Chan KA, Buring JE, Hennekens CH, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003;108:1191-1195.

  43. Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the US Food and Drug Administration. Disponible en http://www.fda.gov/ohrms/dockets/ac/cder05.html




2020     |     www.medigraphic.com